Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 02-Nov-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Mesalamine Extended-Release Capsules USP, 0.375 g.
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 02-Nov-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Mesalamine Extended-Release Capsules USP, 0.375 g.